SYNTHESIS OF TELAPREVIR AND BOCEPREVIR, OR PHARMACEUTICALLY ACCEPTABLE SALTS OR SOLVATES AS WELL AS INTERMEDIATE PRODUCTS THEREOF INCLUDING beta-AMINO ACIDS PREPARED VIA MUKAIYAMA ALDOL ADDITION

摘要

The invention relates to synthetic routes for preparing telaprevir and boceprevir, and its intermediates as well as peptides other than telaprevir. The synthetic routes are based on a Mukaiyama aldol addition reaction of a silyl enol ether or an enolate with an imine. The invention also refers to novel intermediates for preparing telaprevir/boceprevir or other peptides.

主权项

1. Process for the preparation of telaprevir of Formula 1or boceprevir according to Formula 25or a pharmaceutically acceptable salt or solvate thereof, comprising the steps of:
i) providing a compound of Formula 2a or 2b ii) bringing the compound of Formula 2a or 2b into contact with a compound of Formula 3 wherein R4 and R5 are independently methyl or ethyl; and R6 is methyl or ethyl in the presence of an acid, thereby obtaining a compound of Formula 4a or 4b′ wherein R4 and R5 are as defined above, wherein optionally the stereochemical purity of the compound of Formula 4a is improved by extraction of said compound from the reaction mixture; iii) conducting the steps of (a) deprotecting the compound of Formula 4a or 4b′ in order to provide a NH2-group and (b) protecting the obtained NH2-group, either separately or as a one-pot process, in order to provide a compound of Formula 5a or 5b′ wherein R4 and R5 are as defined above; and R9 is a protective group; iv) conducting the steps of (a) hydrolyzing the compound of Formula 5a or 5b′ in order to substitute the OR5-group with an OH-group and (b) performing an amine coupling reaction of the compound of Formula 5a with said OH-group with cyclopropylamine in the presence of one or more coupling agents in order to provide a compound of Formula 6a or reacting the compound of Formula 5b′ with said OH-group with an ammonia source in the presence of one or more coupling agents in order to provide a compound of Formula 6b′ wherein R4 and R9 are as defined above; v) deprotecting the compound of Formula 6a or 6b′ in order to provide a compound of Formula 7a or 7b′, wherein R4 is as defined above; vi) bringing the compound of Formula 7a into contact with a compound of Formula 8a or bringing the compound of Formula 7b′ into contact with compound of Formula 8b in the presence of one or more coupling agents, thereby obtaining a compound of Formula 9a or 9b′, vii) deprotecting/cleaving the acetal in the compound of Formula 9a or 9b′ in the presence of an acid thereby obtaining telaprevir of Formula 1 or boceprevir according to Formula 25, or a pharmaceutically acceptable salt or solvate thereof.